Comparative Pharmacology
Head-to-head clinical analysis: EMRELIS versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMRELIS versus VONTROL.
EMRELIS vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
100 mg subcutaneously once weekly.
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antiemetic
Antiemetic